REGN

Regeneron Pharmaceuticals, Inc. - 10-Q Summary (Q3 2005)

Business Context and Reporting Period

This filing covers the quarterly period ended September 30, 2005. Regeneron is a biopharmaceutical company focused on discovering and developing pharmaceutical products for serious medical conditions. Key strategic focuses include the development of the VEGF Trap (for oncology and eye diseases) and the IL-1 Trap (for inflammatory indications). The company has no products currently available for commercial sale and relies on collaboration agreements and contract manufacturing for revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased significantly year-over-year (55% drop in Q3, 62% drop for 9 months). This is primarily due to reduced reimbursement from the sanofi-aventis collaboration (lower VEGF Trap manufacturing costs) and the expiration of the Procter & Gamble collaboration in June 2005.
• Accounting Change Impact: Effective January 1, 2005, the company adopted SFAS 123, recognizing stock-based compensation expense. This added $5.5 million to Q3 expenses and $16.2 million to 9-month expenses, materially increasing reported losses compared to 2004.
• One-Time Income: The 9-month 2005 period included $30.6 million in "Other contract income" (non-recurring), comprising a $25.0 million payment from sanofi-aventis for an agreement amendment and a $5.6 million payment from Procter & Gamble upon collaboration termination.
• Profitability Shift: The company swung from a net income of $38.9 million in the first nine months of 2004 to a net loss of $65.8 million in the same period of 2005.

Guidance, Outlook, and Risks

• Workforce Reduction: In September 2005, Regeneron announced a plan to reduce its workforce from 730 to approximately 565 by the end of 2006. Estimated severance costs are between $2.5 million and $3.0 million, with the majority expected in Q4 2005.
• Liquidity Outlook: Management believes existing capital resources will fund operations through at least mid-2008. However, this depends on the success of clinical trials and the continuation of the sanofi-aventis collaboration.
• Clinical Pipeline:
  • VEGF Trap (Oncology): Plans to initiate up to 19 additional trials in various cancer indications.
  • VEGF Trap (Eye Diseases): Phase 1 trial for wet AMD completed; Phase 2 trial expected to begin late 2005 or early 2006.
  • IL-1 Trap: Positive preliminary data in CAPS (rare disease); proof-of-concept studies planned for SoJIA and PMR. Development in adult rheumatoid arthritis was discontinued.
• Risks: Significant risks include the uncertainty of clinical trial outcomes, potential termination of the sanofi-aventis collaboration (which funds development), patent litigation (specifically regarding Genentech patents), and the need for additional financing if capital is consumed faster than projected.

Investor Verification Checklist

• Collaboration Stability: Verify the status of the sanofi-aventis agreement, as it funds the majority of VEGF Trap development and provides significant revenue.
• Stock-Based Compensation: Review the impact of SFAS 123 adoption on future earnings, as non-cash stock option expenses will continue to inflate operating losses.
• Debt Maturity: Confirm the company's ability to service or refinance the $200 million convertible notes maturing in October 2008.
• Revenue Run-Rate: Assess the sustainability of revenue streams post-2006, given the expiration of the Merck contract manufacturing agreement and the Procter & Gamble collaboration.
• Severance Costs: Monitor Q4 2005 results for the recognition of the estimated $2.5–$3.0 million workforce reduction costs.